Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma

Saved in:
Bibliographic Details
Published in:Journal of managed care & specialty pharmacy 2021-11, Vol.27 (11), p.1513-1525
Main Authors: Paul, Eleanor, Konidaris, Gerasimos, Cope, Shannon, Chen, Chieh-I, Keeping, Sam, Xu, Yingxin, Atsou, Kokuvi, Ayers, Dieter, Guyot, Patricia, Sasane, Medha, Mojebi, Ali, Kuznik, Andreas
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c397t-1d8b1d6dd963ebbb91df9d5e73cd67c0889813d7589ed43180a0c218ae999f9b3
cites cdi_FETCH-LOGICAL-c397t-1d8b1d6dd963ebbb91df9d5e73cd67c0889813d7589ed43180a0c218ae999f9b3
container_end_page 1525
container_issue 11
container_start_page 1513
container_title Journal of managed care & specialty pharmacy
container_volume 27
creator Paul, Eleanor
Konidaris, Gerasimos
Cope, Shannon
Chen, Chieh-I
Keeping, Sam
Xu, Yingxin
Atsou, Kokuvi
Ayers, Dieter
Guyot, Patricia
Sasane, Medha
Mojebi, Ali
Kuznik, Andreas
description
doi_str_mv 10.18553/jmcp.2021.21164
format article
fullrecord <record><control><sourceid>pubmedcentral_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10394223</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_10394223</sourcerecordid><originalsourceid>FETCH-LOGICAL-c397t-1d8b1d6dd963ebbb91df9d5e73cd67c0889813d7589ed43180a0c218ae999f9b3</originalsourceid><addsrcrecordid>eNpVkclOwzAQhi0EolXpnaNfIMVLNp8QqtikSlzgbHmZgKskDnYSqTw9SVshcZrRLL_mnw-hW0o2tMwyfrdvTLdhhNENozRPL9CS8SJPKOHs8pyTLCULtI5xTwhhPMtLyq_Rgqc8o4ymSzRufewTqCowvRuhhRixalV9iC5iX2EDjetq1yiNx4g7aHTwtfsZ5kLlA-4DqL6Btp-HlR1Va8BiM_SqBT9EHL8H1cyJgbrGRgXjWt-oG3RVqTrC-hxX6OPp8X37kuzenl-3D7vEcFH0CbWlpja3VuQctNaC2krYDApubF4YUpZiMmSLrBRgU05LoohhtFQghKiE5it0f9LtBt2ANdOhQdWyC5OjcJBeOfm_07ov-elHOT1RpIzxSYGcFEzwMQao_pYpkUcOcuYgZw7yyIH_Aodlfxw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma</title><source>PubMed Central Free</source><creator>Paul, Eleanor ; Konidaris, Gerasimos ; Cope, Shannon ; Chen, Chieh-I ; Keeping, Sam ; Xu, Yingxin ; Atsou, Kokuvi ; Ayers, Dieter ; Guyot, Patricia ; Sasane, Medha ; Mojebi, Ali ; Kuznik, Andreas</creator><creatorcontrib>Paul, Eleanor ; Konidaris, Gerasimos ; Cope, Shannon ; Chen, Chieh-I ; Keeping, Sam ; Xu, Yingxin ; Atsou, Kokuvi ; Ayers, Dieter ; Guyot, Patricia ; Sasane, Medha ; Mojebi, Ali ; Kuznik, Andreas</creatorcontrib><identifier>ISSN: 2376-0540</identifier><identifier>EISSN: 2376-1032</identifier><identifier>DOI: 10.18553/jmcp.2021.21164</identifier><identifier>PMID: 34351214</identifier><language>eng</language><publisher>Academy of Managed Care Pharmacy</publisher><ispartof>Journal of managed care &amp; specialty pharmacy, 2021-11, Vol.27 (11), p.1513-1525</ispartof><rights>Copyright © 2021, Academy of Managed Care Pharmacy. All rights reserved. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c397t-1d8b1d6dd963ebbb91df9d5e73cd67c0889813d7589ed43180a0c218ae999f9b3</citedby><cites>FETCH-LOGICAL-c397t-1d8b1d6dd963ebbb91df9d5e73cd67c0889813d7589ed43180a0c218ae999f9b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394223/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394223/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Paul, Eleanor</creatorcontrib><creatorcontrib>Konidaris, Gerasimos</creatorcontrib><creatorcontrib>Cope, Shannon</creatorcontrib><creatorcontrib>Chen, Chieh-I</creatorcontrib><creatorcontrib>Keeping, Sam</creatorcontrib><creatorcontrib>Xu, Yingxin</creatorcontrib><creatorcontrib>Atsou, Kokuvi</creatorcontrib><creatorcontrib>Ayers, Dieter</creatorcontrib><creatorcontrib>Guyot, Patricia</creatorcontrib><creatorcontrib>Sasane, Medha</creatorcontrib><creatorcontrib>Mojebi, Ali</creatorcontrib><creatorcontrib>Kuznik, Andreas</creatorcontrib><title>Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma</title><title>Journal of managed care &amp; specialty pharmacy</title><issn>2376-0540</issn><issn>2376-1032</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpVkclOwzAQhi0EolXpnaNfIMVLNp8QqtikSlzgbHmZgKskDnYSqTw9SVshcZrRLL_mnw-hW0o2tMwyfrdvTLdhhNENozRPL9CS8SJPKOHs8pyTLCULtI5xTwhhPMtLyq_Rgqc8o4ymSzRufewTqCowvRuhhRixalV9iC5iX2EDjetq1yiNx4g7aHTwtfsZ5kLlA-4DqL6Btp-HlR1Va8BiM_SqBT9EHL8H1cyJgbrGRgXjWt-oG3RVqTrC-hxX6OPp8X37kuzenl-3D7vEcFH0CbWlpja3VuQctNaC2krYDApubF4YUpZiMmSLrBRgU05LoohhtFQghKiE5it0f9LtBt2ANdOhQdWyC5OjcJBeOfm_07ov-elHOT1RpIzxSYGcFEzwMQao_pYpkUcOcuYgZw7yyIH_Aodlfxw</recordid><startdate>202111</startdate><enddate>202111</enddate><creator>Paul, Eleanor</creator><creator>Konidaris, Gerasimos</creator><creator>Cope, Shannon</creator><creator>Chen, Chieh-I</creator><creator>Keeping, Sam</creator><creator>Xu, Yingxin</creator><creator>Atsou, Kokuvi</creator><creator>Ayers, Dieter</creator><creator>Guyot, Patricia</creator><creator>Sasane, Medha</creator><creator>Mojebi, Ali</creator><creator>Kuznik, Andreas</creator><general>Academy of Managed Care Pharmacy</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>202111</creationdate><title>Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma</title><author>Paul, Eleanor ; Konidaris, Gerasimos ; Cope, Shannon ; Chen, Chieh-I ; Keeping, Sam ; Xu, Yingxin ; Atsou, Kokuvi ; Ayers, Dieter ; Guyot, Patricia ; Sasane, Medha ; Mojebi, Ali ; Kuznik, Andreas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c397t-1d8b1d6dd963ebbb91df9d5e73cd67c0889813d7589ed43180a0c218ae999f9b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Paul, Eleanor</creatorcontrib><creatorcontrib>Konidaris, Gerasimos</creatorcontrib><creatorcontrib>Cope, Shannon</creatorcontrib><creatorcontrib>Chen, Chieh-I</creatorcontrib><creatorcontrib>Keeping, Sam</creatorcontrib><creatorcontrib>Xu, Yingxin</creatorcontrib><creatorcontrib>Atsou, Kokuvi</creatorcontrib><creatorcontrib>Ayers, Dieter</creatorcontrib><creatorcontrib>Guyot, Patricia</creatorcontrib><creatorcontrib>Sasane, Medha</creatorcontrib><creatorcontrib>Mojebi, Ali</creatorcontrib><creatorcontrib>Kuznik, Andreas</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of managed care &amp; specialty pharmacy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Paul, Eleanor</au><au>Konidaris, Gerasimos</au><au>Cope, Shannon</au><au>Chen, Chieh-I</au><au>Keeping, Sam</au><au>Xu, Yingxin</au><au>Atsou, Kokuvi</au><au>Ayers, Dieter</au><au>Guyot, Patricia</au><au>Sasane, Medha</au><au>Mojebi, Ali</au><au>Kuznik, Andreas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma</atitle><jtitle>Journal of managed care &amp; specialty pharmacy</jtitle><date>2021-11</date><risdate>2021</risdate><volume>27</volume><issue>11</issue><spage>1513</spage><epage>1525</epage><pages>1513-1525</pages><issn>2376-0540</issn><eissn>2376-1032</eissn><pub>Academy of Managed Care Pharmacy</pub><pmid>34351214</pmid><doi>10.18553/jmcp.2021.21164</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2376-0540
ispartof Journal of managed care & specialty pharmacy, 2021-11, Vol.27 (11), p.1513-1525
issn 2376-0540
2376-1032
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10394223
source PubMed Central Free
title Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T20%3A35%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost-effectiveness%20analysis%20of%20cemiplimab%20vs%20pembrolizumab%20for%20treatment%20of%20advanced%20cutaneous%20squamous%20cell%20carcinoma&rft.jtitle=Journal%20of%20managed%20care%20&%20specialty%20pharmacy&rft.au=Paul,%20Eleanor&rft.date=2021-11&rft.volume=27&rft.issue=11&rft.spage=1513&rft.epage=1525&rft.pages=1513-1525&rft.issn=2376-0540&rft.eissn=2376-1032&rft_id=info:doi/10.18553/jmcp.2021.21164&rft_dat=%3Cpubmedcentral_cross%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_10394223%3C/pubmedcentral_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c397t-1d8b1d6dd963ebbb91df9d5e73cd67c0889813d7589ed43180a0c218ae999f9b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/34351214&rfr_iscdi=true